Table 1.

Association of baseline Galectin-3 and ST-2 with 30% decline of kidney function among participants in the Cardiovascular Health Study (N=2,763)

Biomarker	#w/ 30% decline	Unadjusted	Model 1	Model 2
Galectin-3		OR (95% CI)	OR (95% CI)	OR (95% CI)
Continuous (per SD = 6)	247	1.09 (0.97, 1.22)	0.92 (0.79, 1.08)	0.90 (0.77, 1.06)
Quartiles
<12.77	62	1.00 (ref)	1.00 (ref)	1.00 (ref)
12.77 – 15.63	61	1.03 (0.71, 1.51)	0.92 (0.63, 1.37)	0.93 (0.63, 1.38)
15.64 – 19.18	62	1.10 (0.76, 1.61)	0.86 (0.57, 1.27)	0.84 (0.56, 1.26)
>19.18	62	1.19 (0.81, 1.75)	0.65 (0.41, 1.01)	0.62 (0.39, 1.00)
ST-2
Continuous (per SD = 10)	247	1.16 (1.04, 1.30)*	1.07 (0.94, 1.22)	1.03 (0.90, 1.18)
Quartiles
<18.84	56	1.00 (ref)	1.00 (ref)	1.00 (ref)
18.84 – 23.62	56	1.04 (0.70, 1.54)	0.91 (0.61, 1.36)	0.90 (0.60, 1.34)
23.63 – 29.72	66	1.31 (0.89, 1.91)	1.04 (0.70, 1.55)	0.98 (0.66, 1.47)
> 29.72	69	1.60 (1.09, 2.34)	1.18 (0.78, 1.78)	1.07 (0.70, 1.62)

Model 1: adjusted for age, gender, race, baseline estimated glomerular filtration rate (eGFR), body mass index (BMI), systolic blood pressure, hypertension medications, diabetes, smoking, LDL cholesterol, HDL cholesterol and prevalent cardiovascular disease (defined as coronary heart disease or stroke)

Model 2: Model 1 + NTproBNP and troponin T

^*p<0.05